James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application - a podcast by PVI, PeerView Institute for Medical Education

from 2023-12-12T19:38:55.879715

:: ::

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.

FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from argenx US, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.


Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.


Faculty/Planner
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.


Faculty/Planner
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Further episodes of PeerView Family Medicine

Further podcasts by PVI, PeerView Institute for Medical Education

Website of PVI, PeerView Institute for Medical Education